Novotech has been named as a finalist in the Health and Biotechnology category of the upcoming 2017 Premier’s New South Wales Export Awards.
“Novotech has had a terrific year of growth providing Australian clinical trial services to international clients. In the coming year, we will continue to invest heavily in promoting the entire sector working with Austrade and State-based trade organisations,” said Novotech CEO Dr John Moller.
While Novotech is one of the largest full service CROs in the Asia Pacific region; it is headquartered in Sydney, having established its first office in the city in 1996.
For more information about the award, please visit the Premier’s NSW Export Awards website
For more information about the untapped clinical trial benefits available in Australia, download a free copy of the Frost & Sullivan white papers, ‘Australia: Preferred Destination for Early Stage Research or feel free to contact us.
About Novotech - www.novotech-cro.com
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region. Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence included running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0
Corporate enquiries: Please contact Marketing & Communications Manager Justine Lamond on +61 2 8569 1458 or email@example.com